Bluebird

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Certification, Ethics, Complaint, Suite, Bluebird, FDA, Bluebird bio, Security (finance)

Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

Retrieved on: 
Monday, April 1, 2024
Titan, Patient, Class, Food and Drug Administration, Advertising, Bluebird, FDA, Court, Bluebird bio, Tobacco

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

Retrieved on: 
Sunday, March 31, 2024
Annual report, Prior, Organization, Policy, News, LLP, Bank statement, Pomerantz, Bluebird, Bluebird bio

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE).
  • The investigation concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, SAN, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, FDA, BLA, Bluebird bio, Food, Person, Pharmaceutical industry

SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.

Key Points: 
  • SAN DIEGO, March 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Saturday, March 30, 2024
Sickle cell disease, Biotechnology, Bluebird bio, SAN, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Pharmaceutical industry

), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE

Retrieved on: 
Friday, March 29, 2024
Titan, News, EY, Bank statement, Advertising, Bluebird, Audit committee, Audit

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Friday, March 29, 2024
Certification, Ethics, Complaint, Suite, Bluebird, FDA, Bluebird bio, Security (finance)

Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit

Retrieved on: 
Thursday, March 28, 2024
Sickle cell disease, Biotechnology, Bluebird bio, SAN, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Pharmaceutical industry

), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.

BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Tuesday, April 9, 2024
Class Action Lawsuit, Professional Services, Legal, Sickle cell disease, Biotechnology, Bluebird bio, DSM-IV codes, Patient, History, News, Cancer, Complaint, SCD, Bluebird, Food, FDA, BLA, Tobacco

), the bluebird bio class action lawsuit charges bluebird bio as well as certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the bluebird bio class action lawsuit charges bluebird bio as well as certain of bluebird bio’s top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the bluebird bio class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the bluebird bio class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the bluebird bio class action lawsuit.

KARORA RESOURCES ANNOUNCES MERGER TRANSACTION WITH WESTGOLD RESOURCES

Retrieved on: 
Monday, April 8, 2024
CIBC, Agreement, GDX, Westgold Resources, Sale, G&A, AWST, OTCQX, Corporate spin-off, CBCA, Policy, Toronto Stock Exchange, KRR, Combined, Big Bell, Arrangement, Index, Safety, VWAP, Multilateral, Bluebird, ASX, TSX, Stikeman Elliott, Canada Business Corporations Act, Transaction, Good, Mining, Shareholder Meeting, Growth, Gold, FIRB, Security (finance)

TORONTO, April 7, 2024 /CNW/ - Karora Resources Inc. (TSX: KRR) (OTCQX: KRRGF) ("Karora") and Westgold Resources Limited (ASX: WGX) (OTCQX: WGXRF) ("Westgold") have agreed to combine in a merger pursuant to which Westgold will acquire 100% of the issued and outstanding common shares of Karora ("Karora Shares") by way of a statutory plan of arrangement under the Canada Business Corporations Act ("CBCA") ("Transaction").

Key Points: 
  • TORONTO, April 7, 2024 /CNW/ - Karora Resources Inc. (TSX: KRR) (OTCQX: KRRGF) ("Karora") and Westgold Resources Limited (ASX: WGX) (OTCQX: WGXRF) ("Westgold") have agreed to combine in a merger pursuant to which Westgold will acquire 100% of the issued and outstanding common shares of Karora ("Karora Shares") by way of a statutory plan of arrangement under the Canada Business Corporations Act ("CBCA") ("Transaction").
  • Karora shareholders will receive 2.5241 Westgold fully paid ordinary shares ("Westgold Shares"), A$0.68 (C$0.611) in cash and 0.30 of a share in a new company to be spun-out from Karora ("SpinCo") for each Karora Share held at the closing of the Transaction ("Offer Consideration").
  • Upon completion of the Transaction, existing Westgold and Karora shareholders will own approximately 50.1% and 49.9% of Enlarged Westgold, respectively.
  • The Transaction has been unanimously approved by the boards of directors of Westgold and Karora, and Karora's board of directors unanimously recommends that Karora shareholders vote in favour of the Transaction.